Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Other Articles & Publications
Journal of Clinical Oncology
February 14, 2025
,
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO)-GI)
January 25, 2025
,
Fakih, et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable, locally advanced pMMR or dMMR colon cancer: results from the UNICORN trial by GONO
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)
January 25, 2025
,
Ghelardi et al.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Neoadjuvant Botensilimab (BOT) Plus Balstilimab (BAL) in Resectable Mismatch Repair Proficient (pMMR) and Deficient (dMMR) Colorectal Cancer (CRC)
ASCO
American Society for Clinical Oncology, Gastrointestinal (ASCO- GI)
January 25, 2025
,
Hissong et al.